Last reviewed · How we verify
Cutia Therapeutics(Wuxi)Co.,Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
1 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| CU-40102 Spray | CU-40102 Spray | phase 3 | Dermatology | |||
| Lidocaine tetracaine cream | Lidocaine tetracaine cream | phase 3 | Local anesthetic combination | Voltage-gated sodium channels | Dermatology |
Therapeutic area mix
- Dermatology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Cedars-Sinai Medical Center · 1 shared drug class
- East Carolina University · 1 shared drug class
- Galderma R&D · 1 shared drug class
- Hadassah Medical Organization · 1 shared drug class
- University of Alabama at Birmingham · 1 shared drug class
- University of Belgrade · 1 shared drug class
- University of New Mexico · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cutia Therapeutics(Wuxi)Co.,Ltd:
- Cutia Therapeutics(Wuxi)Co.,Ltd pipeline updates — RSS
- Cutia Therapeutics(Wuxi)Co.,Ltd pipeline updates — Atom
- Cutia Therapeutics(Wuxi)Co.,Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cutia Therapeutics(Wuxi)Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cutia-therapeutics-wuxi-co-ltd. Accessed 2026-05-16.